Global X Genomics & Biotechnology ETF Rating $9.35 +0.21 (+2.30%) Closing price 03:59 PM EasternExtended Trading$9.35 0.00 (0.00%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock Global X Genomics & Biotechnology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.GNOM Aggregate RatingModerate Buy 2.70Holdings in GNOM have an aggregate rating of Moderate Buy based on 389 analyst ratings issued in the past year covering 23 companies (79.3% of the portfolio).GNOM Aggregate Price Target$9.35High Prediction$9.35Average Prediction$9.35Low Prediction$9.35Holdings in GNOM have an aggregate price target of $9.35 and a range of $9.35 to $9.35 covering 23 companies (79.3% of the portfolio).GNOM Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Global X Genomics & Biotechnology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 GNOM Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.42%ALNYAlnylam Pharmaceuticals$454.38-2.8%4.1903 of 5 stars2.85$405.33 -10.8%26News CoverageInsider Trade5.62%CRSPCRISPR Therapeutics$54.32+2.8%3.8242 of 5 stars2.50$71.60 31.8%164.80%ILMNIllumina$101.80+2.5%4.6582 of 5 stars2.25$124.58 22.4%20Positive News4.56%QGENQiagen$49.71+1.2%3.836 of 5 stars2.27$49.69 -0.1%114.52%RNAAvidity Biosciences$46.35+3.8%3.2033 of 5 stars3.06$67.00 44.6%18Positive NewsInsider TradeOptions Volume4.37%LEGNLegend Biotech$35.56+0.1%3.8195 of 5 stars3.00$72.38 103.5%104.23%TECHBio-Techne$57.09+5.7%4.8158 of 5 stars2.69$69.42 21.6%13Positive NewsDividend AnnouncementAnalyst Upgrade4.02%MRNAModerna$27.12+3.4%4.4457 of 5 stars2.04$42.88 58.1%24Analyst Forecast3.63%BMRNBioMarin Pharmaceutical$58.58+0.9%4.9978 of 5 stars2.72$93.17 59.1%25Positive News3.63%VRTXVertex Pharmaceuticals$395.12-0.6%4.8599 of 5 stars2.56$497.10 25.8%27Positive News3.61%BNTXBioNTech$110.88+0.1%1.8334 of 5 stars2.76$135.80 22.5%173.51%GHGuardant Health$61.40+0.2%3.2598 of 5 stars3.06$57.50 -6.4%17Positive News3.50%NTRANatera$165.60+2.3%3.4345 of 5 stars3.06$193.19 16.7%183.20%WGSGeneDx$128.66+6.6%2.253 of 5 stars2.75$101.63 -21.0%8Positive NewsInsider Trade2.94%RAREUltragenyx Pharmaceutical$29.78+0.9%4.7249 of 5 stars2.92$81.50 173.7%12News Coverage2.40%TWSTTwist Bioscience$28.59+8.0%4.1802 of 5 stars2.73$49.40 72.8%11Positive News2.30%VCYTVeracyte$31.00+5.3%2.8602 of 5 stars2.70$40.90 31.9%10News CoveragePositive News2.30%ARWRArrowhead Pharmaceuticals$21.33+2.8%3.7734 of 5 stars3.00$43.14 102.3%92.09%AAgilent Technologies$121.49+3.7%4.8825 of 5 stars2.54$139.77 15.0%13News CoveragePositive NewsUpcoming Earnings2.05%BEAMBeam Therapeutics$16.64+3.9%2.293 of 5 stars3.07$48.45 191.2%142.05%GILDGilead Sciences$114.77-1.2%4.9726 of 5 stars2.88$115.39 0.5%26Trending NewsAnalyst Upgrade1.77%LLYEli Lilly and Company$710.73+0.1%4.9993 of 5 stars2.65$950.17 33.7%23Trending News1.76%BMYBristol Myers Squibb$47.84-1.2%4.7834 of 5 stars2.24$56.38 17.8%21Trending News This page (NASDAQ:GNOM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access